N/A N=168 Magnetic Resonance Imaging Study of Acute Pancreatitis
Acute Pancreatitis
Primary: The T2* Values in the Diagnosis of AP — 25.86; 21.06 ms — p=<0.01
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=83 Pentoxifylline Treatment in Acute Pancreatitis (AP)
Acute Pancreatitis (AP) · Gallstone Pancreatitis · Alcoholic Pancreatitis
Primary: Change in C-reactive Protein (C-RP) From Admission Baseline at One Week. — 86.2; 75.8; 116.4; 127.2 mg/L — p=0.5796
Phase 3 N=42 A Randomized Controlled Pilot Trial of Indomethacin in Acute Pancreatitis
Acute Pancreatitis
Primary: Systemic Inflammatory Response Syndrome (SIRS) Score — -0.96; -1 score on a scale — p=0.87
Phase 2 N=7 A PK/PD Study of CM4620-IE in Patients With Acute Pancreatitis
Acute Pancreatitis
Primary: Exploratory: Percentage Change in IL-2 Production Relative to Pre-dose Values — -55.5 percentage of change in IL-2 production
N/A N=148 SpHincterotomy for Acute Recurrent Pancreatitis
Pancreatitis · Pancreas Divisum · Pancreatitis, Acute
Primary: Reduce the Risk of Subsequent Acute Pancreatitis Episodes by 33% — 32; 26 Participants
Phase 2 N=80 Neostigmine Treatment of Acute Pancreatitis Combined With Intra-abdominal Hypertension
Acute Pancreatitis · Intra-abdominal Hypertension
Primary: Percent Change of IAP After Treatment — -18.7; -5.4; -27.2; -20.0 percent change of IAP
Early Phase 1 N=28 Pentoxifylline Treatment of Acute Pancreatitis
Acute Pancreatitis
Primary: Change in C-Reactive Protein (CRP) — 48.4; 60.6; 62; 154 mg/L — p=0.62
N/A N=394 Urine Trypsinogen 2 Dipstick for the Early Detection of Post-ERCP Pancreatitis
Post-ERCP Acute Pancreatitis
Primary: Sensitivity and Specificity of Urine Trypsinogen-2 Dipstick Testing for the Diagnosis of Post-ERCP Pancreatitis — 11.1; 91; 4.4; 96.5 percentage of participants
Phase 2 N=21 CM4620 Injectable Emulsion Versus Supportive Care in Patients With Acute Pancreatitis and SIRS
Acute Pancreatitis · Systemic Inflammatory Response Syndrome
Primary: The Safety and Tolerability of CM4620-IE in Patients With Acute Pancreatitis and Accompanying Systemic Inflammatory Response Syndrome (SIRS) or Hypoxemia. — 7; 5; 3; 0…
Phase 2 N=60 Fecal Microbiota Transplantation for Pancreatitis
Acute Pancreatitis · Intestinal Bacteria Flora Disturbance · Intestinal Dysfunction
Primary: Number of Participants With Gastrointestinal Failure Score Equal 0 — 12; 14 Participants
Phase 4 N=43 Anti-inflammatory Therapy to Improve Outcomes After TPIAT
Pancreatitis, Chronic; Diabetes; Transplant
Primary: Maximal Acute C-peptide Response to Glucose (ACRmax) — 1.06; 1.52; 1.29 ng/mL*min
Phase 2 N=25 Chronic Pancreatitis. Effect of Pioglitazone on Endocrine Function, Exocrine Function & Structure, Pain & Life Quality
Chronic Pancreatitis · Insulin Resistance · Normal or Mildly Abnormal Stool Fat Levels
Primary: Glucose Tolerance at 24 Weeks — 2; 4; 3; 4 Participants
N/A N=57 MRCP: A Reliable, Non Invasive Method for Staging Chronic Pancreatitis in Pediatrics
Healthy Volunteers
Primary: Total Secreted Fluid Volume as Measured by MR-PFT — 79 mL
Phase 2 N=216 A Study of Auxora in Patients With Acute Pancreatitis and Accompanying SIRS
Acute Pancreatitis · Systemic Inflammatory Response Syndrome
Primary: Median Time to Solid Food Tolerance, With gMCP Modeling Analysis for Dose-response Relationship — 67.0; 64.0; 78.0; 66.0 Hours — p=0.3184
Phase 2 N=48 Alpha-1 Antitrypsin (AAT) Enhances Islet Autograft Survival in Patients With Chronic Pancreatitis
Chronic Pancreatitis
Primary: Islet Graft Function — 233; 354 ng/ml*min
Phase 3 N=82 A Randomized, Double-Blind, Dose Response-Control, Crossover Study to Evaluate the Safety and Efficacy of Two Doses of EUR-1008 (APT-1008) in Chronic Pancreatitis (CP) Participants With Exocrine Pancreatic Insufficiency (EPI)
Chronic Pancreatitis · Exocrine Pancreatic Insufficiency
Primary: Percent Coefficient of Fat Absorption (CFA) of Participants Treated With High Dose EUR-1008 and Low Dose EUR-1008 — 88.87; 89.86 percent CFA — p=0.228
Phase 2 N=8 Simvastatin in Reducing Pancreatitis in Patients With Recurrent, Acute or Chronic Pancreatitis
Acute Pancreatitis
Primary: Change in Peak Bicarbonate Concentration, Measured Using Endoscopic Pancreatic Function Test (ePFT) — -8.20; 5.50 mmol/l
N/A N=73 A Trial of Aprepitant For Prevention of Post-Endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis
Pancreatitis
Primary: Number of Post-ERCP Pancreatitis Cases in Participants Who Are Administered Aprepitant and Placebo Prior to ERCP and One Day After ERCP:Assess the Total Number of…
Phase 3 N=54 A Study to Investigate the Effect of Delayed Release Pancrelipase on Maldigestion in Patients With Exocrine Pancreatic Insufficiency Due to Chronic Pancreatitis and Pancreatectomy
Chronic Pancreatitis · Pancreatectomy · Pancreatic Exocrine Insufficiency
Primary: Change of Coefficient of Fat Absorption (CFA) (%) Between Baseline and End of Double-blind (DB) Period. — 31.93; 8.72 Percentage — p=<0.0001
N/A N=14 Pancreatic Endotherapy for Refractory Chronic Pancreatitis
Pancreatic Duct Stone · Pancreatic Duct Stricture · Pancreatic Duct Dilatation
Primary: Percent Change in Average Daily Pain Score on the Numeric Rating Scale — -36.6; -53.7 Percent Change
N/A N=494,679 To Assess the Risk of Acute Pancreatitis in Patients With Type 2 Diabetes Mellitus Treated With Empagliflozin
Diabetes Mellitus, Type 2
Primary: Incidence Rate of Acute Pancreatitis — 10.30; 11.65 Events per 1,000 person-years
N/A N=12,673,496 A Retrospective Cohort Study of Acute Pancreatitis in Relation to Use of Exenatide and Other Antidiabetic Agents
Type 2 Diabetes (Treated With Exenatide or Other Oral Antidiabetic Therapies) · Healthy Subjects (Treated With no Diabetes Therapies)
Primary: Incidence Rates Per 100,000 Person-Years of Likely Acute Pancreatitis (During "Current Use" Period) - Time on Drug Analysis — 219.7; 226.7; 56.2 Cases per 100,000…
Phase 2 N=12 Secretin Infusion for Pain Due to Chronic Pancreatitis
Chronic Pancreatitis
Primary: VAS Score at Baseline, Days 1, 2, 3, 4, 7, 30. — 5.71; 6.04; 4.92; 4.87 units on a scale — p=.25
Phase 2 N=11 Fat Malabsorption in Chronic Pancreatitis
Chronic Pancreatitis
Primary: Malabsorption Blood Test: Difference in Mean HA AUC Between Groups: Subjects With CP Compared to Healthy Subjects — 8.3; 17.7 mg*h/dL — p=<0.001
N/A N=4 Dietary Soy Isoflavones In Chronic Pancreatitis
Chronic Pancreatitis
Primary: Dose Limiting Toxicities — 0; 0; 0; 0 Participants
N/A N=399 Pancreas Resection With and Without Drains
Pancreas Tumor · Pancreatitis
Primary: 60-day ≥ Grade II Complication Rate — 72; 76 Participants — p=0.804
N/A N=66 Incorporating Endoscopic Ultrasound and Elastography Towards Improving Outcomes of Pediatric Pancreatitis Management
Chronic Pancreatitis · Acute Recurrent Pancreatitis
Primary: EUS Pancreatic Findings- Rosemont Criteria — 36; 0; 26; 0 percentage of participants
Phase 3 N=170 Secretin Infusion to Prevent Pancreatic Leaks Following Pancreatic Resection
Injury of Body of Pancreas
Primary: Number of Participants With Biochemical Leak/Grade B Fistula/Grade C Fistula — 25; 16; 3; 5 Participants
N/A N=101 Role of Pancreatic Triglyceride Content in Beta-cell Function
Obesity · Type 2 Diabetes
Primary: Pancreatic and Liver Fat — 1.87; 6.57; 3.61; 5.85 percent
Phase 3 N=19 Study of Pancreatic Enzyme Product in Pediatric Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency
Cystic Fibrosis · Exocrine Pancreatic Insufficiency
Primary: Percentage of Participants Who Were Responders After 1 Week of Treatment With Study Medication — 68.4 percentage of participants